Form 8-K - Current report:
SEC Accession No. 0001193125-24-219153
Filing Date
2024-09-16
Accepted
2024-09-16 06:05:30
Documents
15
Period of Report
2024-09-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d862522d8k.htm   iXBRL 8-K 30997
2 EX-99.1 d862522dex991.htm EX-99.1 67316
6 GRAPHIC g862522g0913031014890.jpg GRAPHIC 3191
  Complete submission text file 0001193125-24-219153.txt   244565

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nuvl-20240914.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nuvl-20240914_lab.xml EX-101.LAB 18758
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nuvl-20240914_pre.xml EX-101.PRE 11713
17 EXTRACTED XBRL INSTANCE DOCUMENT d862522d8k_htm.xml XML 3780
Mailing Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142 508-446-2272
Nuvalent, Inc. (Filer) CIK: 0001861560 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40671 | Film No.: 241299244
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)